Compare Mesoblast Limited (MESO) vs Energy Select Sector SPDR Fund (XLE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mesoblast Limited vs Energy Select Sector SPDR Fund — how do they compare? Mesoblast Limited trades at $16.87 (market cap $2.21B), while Energy Select Sector SPDR Fund trades at $60.73. The key difference: Energy Select Sector SPDR Fund is trading nearer its 52-week high, Mesoblast Limited nearer its low. Which is the better fit depends on your goals.
| MESO | XLE | |
|---|---|---|
Market Cap | $2.21B | — |
Sector | Technology | — |
52-Week High | $20.96 | $62.57 |
52-Week Low | $12.88 | $42.33 |
Enterprise Value | $2.21B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
MESO trades at $16.9, up 1.32% on the day, with a bullish technical signal from moving averages. The company reported Ryoncil net revenues of $36 million for the quarter ended June 30, 2026, and achieved its target of 300 patients in a Phase 3 trial for chronic low back pain. Despite strong revenue growth from its commercial launch, fundamentals show a net income margin of -144.33% and negative EBITDA of $80.06 million for 2025, reflecting significant losses amid expansion.
The outlook hinges on commercial execution and regulatory progress, with analyst consensus leaning buy (45% buy ratings). Key risks include high cash burn, dependence on pipeline success, and competitive pressures. Upside potential exists if revenue growth accelerates and losses narrow, but investors face volatility from clinical trial outcomes and funding needs.
XLE trades at $60.47, up 0.47% with a bullish technical signal from moving averages. The ETF has rallied 40.52% over the past year, driven by strong oil prices and geopolitical tensions in the Middle East. Recent earnings from major holdings like ExxonMobil and Chevron showed profit surges, supporting the sector's momentum. Technical indicators show support at $59 and resistance at $61, with RSI readings in neutral territory suggesting room for further movement.
Outlook remains positive but faces geopolitical risks. The energy sector benefits from elevated oil prices and strong earnings, though concentration in a few large stocks and sensitivity to Middle East tensions present volatility. Analyst sentiment is mixed with some calling the entry point less attractive after the rally, while others see continued upside potential from supply disruptions and AI infrastructure demand.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mesoblast Limited
Mesoblast Limited is a global leader in allogeneic cellular medicines. The company develops innovative, commercially-ready mesenchymal lineage cell (MLC) technology for the treatment of various inflammatory and cardiovascular conditions. Their pipeline focuses on leveraging the anti-inflammatory, tissue repair, and immune-modulating properties of these cells for diseases with high unmet medical needs, such as acute graft versus host disease (aGVHD) and chronic heart failure.
Read more on MESO →About Energy Select Sector SPDR Fund
In seeking to track the performance of the index, the fund employs a replication strategy. It generally invests substantially all, but at least 95%, of its total assets in the securities comprising the index. The index includes companies that have been identified as energy companies by the GICS®, including securities of companies from the following industries: oil, gas and consumable fuels; and energy equipment and services. It is non-diversified.
Read more on XLE →
